Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165802 · ClinicalTrials.gov registry record · Phase 1
A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00165802 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 40 participants.
The verdict
NCT00165802, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective therapy or for which no effective therapy exists.
Interventions
- DRUG E7974
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165802
The ClinicalTrials.gov registry entry for NCT00165802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7974 is the first listed.
NCT00165802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165802 about?
NCT00165802 is a clinical study titled "A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors". The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective therapy or for which no effective therapy exists.
What is the current status of trial NCT00165802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00165802?
The interventions under investigation include: E7974 (DRUG).
Who is sponsoring clinical trial NCT00165802?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.